Table 1 Characteristics of the studies included in the literature review and the meta-analysis
Study (Year of publication) | Country | Study design | Inclusion criteria | NPWT used | Standard dressing used | Duration of treatment (days) |
|---|---|---|---|---|---|---|
Atkins et al. [5] | USA | Retrospective study | Diabetes, obesity, prolonged use of cardiopulmonary bypass and the need for intra-aortic balloon pump as well as the use of bilateral mammary arteries graft | VAC “(Kinetic Concepts Inc, San Antonio, TX)” | NA | 2–4 |
Colli et al. [17] | Italy | Prospective study | Mean Fowler risk score 15.1 [8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30] | Prevena™ | NA | 5 |
Grauhan et al. [13] | Germany | Prospective study | BMI > 30 kg/m2, age 18 or more, absence of preoperative signs of inflammation | Prevena™ | NA | 6–7 |
Grauhan et al. [18] | Germany | Prospective study | NA | Prevena™ | NA | 6–7 |
Witt-Majchrzak et al. [19] | Poland | Prospective study | Off pump CABG | PICO™ | NA | 6 |
Santarpino et al. [20] | Germany | Retrospective study | Isolated CABG with BIMA grafting | Prevena™ | Absorbent adhesive dressing (usually Cosmopor E (Paul Hartmann AG, Heidenheim, Germany) | 5 |
Reddy [21] | USA | Retrospective study | At least 3 of the following: BMI > 35 kg/m2, diabetes, low albumin, poor tissue quality at incision, recent post operative infection, steroid, high dosage of pressor medication | Prevena™ | NA | |
Philip et al. [22] | Ireland | Retrospective study | obese, current smoker, hypertensive with COPD and diabetes mellitus | Prevena™ | NA | 6–7 |
Gatti et al. [7] | Italy | Prospective study | Isolated CABG with BIMA grafting | Prevena™ | NA | NA |
Ruggieri et al. [9] | France | Propensity match | Isolated CABG with BIMA grafting | Prevena™ | Tegaderm (3 M Corporate, St. Paul, MN, USA) | 5–7 |
Suleo-Calanao et al. [23] | United Kingdom | Retrospective study | NA | Prevena™ | Opsite Postop (Smith + Nephew Inc., Andover, MA, USA) | 5 |
Tabley et al. [24] | France | Retrospective study | NA | PICO™ | NA | NA |
Rashed et al. [25] | Hungary | Randomized trail | BMI > 30 kg/m2, diabetes, PVD, COPD | VivanoTec | NA | 5 |
Brega et al. [26] | Italy | Prospective study | Two of the following criteria: diabetes on medical treatment, BMI > 30 kg/m2, COPD, diabetes, eGFR < 60 ml/min, BIMA grafting | AVELLE® | Hydrocolloid and carboxymethyl cellulose, or traditional gauzedressing | 7 |
Nguyen et al. [27] | USA | Retrospective cohort study | All nontraumatic cardiothoracic surgery | Prevena™ | NA | NA |